Andy Ferguson

Andy Ferguson

Company: Gritstone Oncology

Job title: VP, Clinical Science


A Novel Heterologous Prime Boost Vaccine System To Drive Tumor Specific T Cell Responses For Cancer Immunotherapy 1:45 pm

• Development of a potent heterologous prime/boost immunization approach to deliver predicted TSNAs to patients, which is comprised of a replication incompetent chimpanzee adenoviral vector (ChAdV) for the prime vaccination and a self-replicating, synthetic viral vector (srRNA) for repeated boost vaccinations • Induction of high titer, polyfunctional and durable T-cell responses against non-self antigens •…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.